Sacubitril-valsartan Versus Enalapril or Losartan at Guideline-Recommended Maximum Dosages in Heart Failure with Reduced Ejection Fraction: Real-World Results from the BEAT-HF Cohort
Authors:
- Renato C. BarrosRBRenato C. Barros
- Vinícius C. FiusaVFVinícius C. Fiusa
- Gabrielle N. TimGTGabrielle N. Tim
- Victoria T. V. GoulartVGVictoria T. V. Goulart
- Caio Henrique M. NascimentoCNCaio Henrique M. Nascimento
- Gustavo T. de MouraGMGustavo T. de Moura
- Adriana J. B. A. GuimarãesAGAdriana J. B. A. Guimarães
- Sergio Henrique Rodolpho RamalhoSRSergio Henrique Rodolpho Ramalho
- Armindo JreigeAJArmindo Jreige
- Filipe A. MouraFMFilipe A. Moura
- Luiz Sérgio Fernandes de CarvalhoLCLuiz Sérgio Fernandes de Carvalho
Preprint
Abstract
Background: Sacubitril-valsartan reduced mortality and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril in pivotal clinical trials. However, these studies used suboptimal dosages of enalapril, potentially limiting their findings. Objective: To compare the outcomes of HFrEF patients treated with sacubitril-valsartan versus either enalapril or losartan at guideline-recommended maximum dosages. Methods: We analyzed data from BEAT-HF, an observational cohort of 2,314 HF patients who received care between Aug/2010 and Jan/2024 at six public hospitals in the Brasília, Brazil. The primary analysis included 254 HFrEF patients receiving the guideline-recommended maximum dosages of the investigated drugs. A sensitivity analysis included 452 patients receiving any sub-maximum dosages. The primary outcome was combined hospitalization or death. Baseline differences were adjusted using propensity score matching. Results: Among 254 HFrEF patients (mean age 63.6±12.3 years, 61.4% male), 115 received sacubitril-valsartan 97/103mg twice daily, 33 enalapril 20mg twice daily, and 106 losartan 100mg daily. Over the median follow-up of 23.9 months [IQR 11.9 – 41.1], there were 70 primary endpoint events (56 first hospitalizations, 32 deaths). Compared to equivalent dosages of enalapril or losartan, sacubitril-valsartan was not associated with significantly reductions in combined hospitalization or death (OR 0.650, 95%CI 0.354 – 1.195, p=0.165), but it was strongly associated with functional status improvement (OR 3.902, 95%CI 1.745 – 8.726, p=0.001). Conclusion: This real-world study wasn’t able to support significant reductions in hospitalization or mortality for sacubitril-valsartan compared with enalapril or losartan at guideline-recommended maximum dosages, suggesting that its benefits may be more modest than previously reported.Keywords
This publication has 11 references indexed in Scilit:
- Sacubitril/valsartan compared to equivalent/sub-equivalent dose angiotensin receptor blocker or angiotensin-converting enzyme inhibitor in heart failure with reduced ejection fraction: a meta-analysis of randomized trialsEuropean Journal of Clinical Pharmacology, 2024
- Efficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HFJournal of Cardiac Failure, 2024
- Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart FailureJACC, 2023
- Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesCirculation, 2022
- Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial InfarctionNew England Journal of Medicine, 2021
- Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection FractionJAMA Cardiology, 2021
- Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart FailureNew England Journal of Medicine, 2019
- Neprilysin Inhibitors: Emerging Therapy for Heart FailureAnnual Review of Medicine, 2017
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- The Natural History of Congestive Heart Failure: The Framingham StudyNew England Journal of Medicine, 1971